More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$32.43B
EPS
0.24
P/E ratio
155.1
Price to sales
40.07
Dividend yield
--
Beta
0.730811
Previous close
$51.57
Today's open
$50.90
Day's range
$50.86 - $52.08
52 week range
$23.62 - $59.97
show more
CEO
JanG.J. van de Winkel
Employees
3029
Headquarters
Valby,
Exchange
Nasdaq Global Select
Shares outstanding
624058550
Issue type
American Depository Receipt
Healthcare
Biotechnology & Life Sciences
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; November 18, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 4,993 restricted stock units and 4,607 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.
GlobeNewsWire • 5 hours ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; November 11, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.
GlobeNewsWire • Nov 11, 2026

Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; November 10, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 164,828 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others.
GlobeNewsWire • Nov 10, 2026

What Genmab A/S (GMAB) Said on Its Q3 Earnings Call
Genmab A/S NASDAQ: GMAB reported 22% revenue growth for the first nine months of 2026 and said it expects full-year revenue to land in the upper part of its existing guidance range, as sales of EPKINLY and royalty income supported growth.
MarketBeat • Nov 5, 2026

Genmab A/S (GMAB) Q3 2026 Earnings Call Transcript
Genmab A/S (GMAB) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 5, 2026

Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that 22 abstracts evaluating epcoritamab, a subcutaneous T-cell engaging bispecific antibody, will be presented or published at the 68th Annual Meeting and Exposition of the American Society of Hematology (ASH), taking place December 12-15, 2026, in New Orleans, Louisiana, and virtually. The breadth of data to be shared at ASH reflects continued progress across the comprehensive epcoritamab development program, incl.
Business Wire • Nov 4, 2026

A little-known biotech's high-stakes cancer bet just paid off and its shares doubled
Genmab shares have doubled in three months after three successful Phase 3 cancer drug trials in October. The Danish biotech is using royalty income from drugs such as Darzalex to fund a shift toward owning more of the medicines it develops and sells.
CNBC • Nov 3, 2026

Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%
Genmab scores a ‘hat trick' with positive data for its experimental cancer drug, petosemtamab, Jefferies says.
Barrons • Oct 28, 2026

Genmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches
Genmab A/S NASDAQ: GMAB said three positive Phase III readouts across lymphoma, ovarian cancer and head and neck cancer could support multiple potential product launches beginning in 2027, as the company seeks to increase growth from medicines it owns or co-develops.
MarketBeat • Oct 28, 2026

Genmab Stock Hits 52-Week High - Here's Why
Genmab A/S (NASDAQ:GMAB) stock surged to a 52-week high after the company delivered positive topline findings from its global Phase 3 LiGeR-HN1 clinical trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting EGFR and LGR5.
Benzinga • Oct 28, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Genmab A/S commission-free¹. Build wealth for the long term using automated trading and transfers.